BINEX Co., Ltd. (KOSDAQ:053030)
South Korea · Delayed Price · Currency is KRW 7,500.00
-160.00 (-2.09%)
Aug 12, 2026, 3:30 PM KST
BINEX Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 164,003 | 168,475 | 130,051 | 154,825 | 156,677 | 134,399 |
Revenue Growth | 17.04% | 29.55% | -16.00% | -1.18% | 16.58% | 1.07% |
Gross Profit Gross Profit Growth | 36,766 | 45,019 | 21,216 | 56,898 | 70,438 | 59,924 |
Operating Income Operating Income Growth | -14,049 | -4,535 | -30,755 | 979.6 | 17,179 | 12,612 |
Net Income Net Income Growth | -12,856 | -3,226 | -35,071 | 4,671 | 12,445 | 19,094 |
Earnings Per Share EPS Growth | -403.67 | -101.29 | -1126.45 | 108.36 | 402.00 | 273.15 |
EPS Growth | - | - | - | -73.05% | 47.17% | 32.87% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Pharmaceuticals Pharmaceuticals Growth | 84,873 | 86,790 | 84,401 | 92,598 | 88,550 | 75,949 |
Bio Bio Growth | 79,131 | 81,685 | 45,644 | 62,227 | 68,115 | 58,414 |
Other Other Growth | - | - | 4.71 | - | 12.29 | 36.51 |
Total Total Growth | 164,003 | 168,475 | 130,051 | 154,825 | 156,677 | 134,399 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 23,259 | 19,614 | 27,793 | 13,454 | 38,203 | 53,474 |
Total Debt Total Debt Growth | 106,698 | 97,126 | 66,050 | 53,507 | 56,152 | 50,451 |
Net Cash (Debt) Net Cash Growth | -83,438 | -77,512 | -38,257 | -40,053 | -17,949 | 3,023 |
Net Cash Growth | - | - | - | - | - | -69.51% |
Net Cash Per Share Net Cash Per Share Growth | -2619.91 | -2433.85 | -1228.78 | -1232.54 | -580.41 | 90.70 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -9,617 | -23,268 | -9,426 | 3,778 | 17,062 | 28,630 |
Capital Expenditures CapEx Growth | -24,154 | -21,215 | -10,366 | -7,747 | -25,933 | -11,850 |
Free Cash Flow Free Cash Flow Growth | -33,771 | -44,483 | -19,792 | -3,969 | -8,871 | 16,780 |
Free Cash Flow Growth | - | - | - | - | - | 37.30% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 22.42% | 26.72% | 16.31% | 36.75% | 44.96% | 44.59% |
Operating Margin | -8.57% | -2.69% | -23.65% | 0.63% | 10.96% | 9.38% |
Pretax Margin | -9.71% | -3.38% | -29.93% | 3.16% | 9.72% | 18.03% |
Profit Margin | -7.84% | -1.92% | -26.97% | 3.02% | 7.94% | 14.21% |
FCF Margin | -20.59% | -26.40% | -15.22% | -2.56% | -5.66% | 12.48% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 59.26 | 28.70 | 24.62 |
Forward PE | 49.16 | 34.58 | 41.42 | 11.62 | 16.77 | 30.43 |
P/FCF Ratio | - | - | - | - | - | 28.01 |
PS Ratio | 1.49 | 2.83 | 4.49 | 1.79 | 2.28 | 3.50 |